97 results about "Sustained-Release Preparations" patented technology

The invention relates to the technical field of food sustained-release preparations, and particularly discloses a sour cherry powder sustained-release preparation with a stable uric acid reducing effect and a preparation process of the sour cherry powder sustained-release preparation. The sour cherry powder sustained-release preparation comprises a core active phase freeze-dried sour cherry powder, a sustained-release carrier phase, a synergistic function phase, an auxiliary regulation phase and a filler, the synergistic functional phase contains a celery seed extract, a curcumin-phospholipid complex, a prebiotic complex and the like, and all the components have a synergistic effect. The preparation method comprises the following steps: carrying out wall breaking, enzymolysis, purification and freeze-drying treatment on sour cherry fruits to obtain a core raw material, compounding the core raw material with other components, and carrying out slow-release carrier construction, coating granulation and other steps to prepare the microcapsule structure preparation. The preparation can be used for assisting in reducing the uric acid level, and has the advantages of high stability of active ingredients, continuous and stable uric acid reducing effect, consideration to intestinal health and the like; the preparation process adopts freeze-drying and micro-capsule coating technologies, effectively retains active ingredients, is controllable in operation, and is suitable for large-scale production.

The invention provides a penicillamine sustained-release preparation. The release rate of the penicillamine sustained-release preparation is adjusted through a specific sustained-release coating. Unexpectedly, the release rate can be obviously improved by adding a small amount of lactose. More unexpectedly, in the prescription system provided by the invention, under the condition that the weight gain of the sustained-release coating is the same, the penicillamine sustained-release preparation which can be released for 12 hours or 24 hours can be respectively obtained only by adjusting the content of lactose, that is, the release rate of the penicillamine sustained-release preparation in 12 hours or 24 hours can reach 85% respectively. According to the penicillamine sustained release preparation provided by the invention, the medication compliance can be improved, and the blood concentration fluctuation can be reduced.

The invention belongs to the technical field of medicines, and particularly relates to a donepezil sustained release preparation and a preparation method thereof, the method comprises the following steps: mixing donepezil, a biodegradable polymer, an amphiphilic polymer and a stabilizer, shearing, curing, and freeze-drying to obtain donepezil microsphere freeze-dried powder. The donepezil sustained release preparation can realize controllable and sustained release of donepezil, the microspheres are good in character and high in stability, meanwhile, the preparation method is simple and convenient, and industrial large-scale production is easy to realize.

The invention relates to the technical field of pharmaceutical preparations, in particular to a solid dispersion-based sustained-release drug composite carrier as well as a preparation method and application thereof. The preparation method comprises the following steps: carrying out synergistic spray drying on double polymers (hydroxypropyl methylcellulose acetate succinate and polyvinylpyrrolidone-vinyl acetate copolymer) to form a solid dispersion; compounding with mesoporous silica and calcium silicate for localization, and spraying ethanol to activate pores; calcium stearate and magnesium stearate are sequentially added for lubrication; prefabricating a sustained-release skeleton master batch; and finally, mixing, rolling and forming. According to the method, through hierarchical structural design, the drug stability, the powder fluidity and the release controllability are remarkably improved, the method is suitable for industrial production of the dihydroergoline mesylate sustained release preparation, and a release curve is smooth and reliable.

The invention discloses a muscle-bone regeneration sustained-release preparation for targeting knee joint cartilage and a preparation process thereof, the preparation is composed of a cartilage targeting peptide modified PLGA-hyaluronic acid composite nanoparticle sustained-release carrier, an active regeneration component, a biocompatible matrix and an anti-inflammatory component, nanoparticles are prepared by a multiple emulsion solvent evaporation method, and targeting peptide is modified; the composite concentrated growth factors, stem cells and traditional Chinese medicine extracts have the functions of targeted enrichment, long-acting slow release, anti-inflammation and cartilage regeneration promotion, and can be used for knee joint cartilage defect repair.

The invention discloses a beta-alanine sustained release preparation, the sustained release preparation takes beta-alanine as a core material and a non-allergen wall material as an embedding material, and the non-allergen wall material is pea protein and / or ethyl cellulose. The sustained-release preparation disclosed by the invention is appropriate in release rate, not only can effectively relieve side effects generated after taking beta-alanine, but also can meet the health-care function of improving athletic ability in a short time, so that the beta-alanine sustained-release preparation disclosed by the invention can be widely applied to foods and / or health-care products.

The invention provides a smearing sustained-release preparation and a preparation method and application thereof, the smearing sustained-release preparation comprises a chemotherapeutic drug component, an immune drug component and a sustained-release auxiliary material, and the smearing sustained-release preparation is in a transparent flowable sol shape. The sustained release preparation disclosed by the invention can be smeared and applied to a focus part in situ after a tumor operation. The application effect comprises the following steps: filling the treatment window period of the traditional postoperative adjuvant chemotherapy, and improving the local drug concentration of the focus through in-situ local slow release of the drug, thereby effectively removing residual tumor tissues and reducing the systemic toxicity of drug treatment; the metastasis and recurrence rate of tumors are further inhibited through the synergistic combined effect of chemotherapy-immune drugs in the preparation. The advantages show that the smearing sustained-release preparation provided by the invention has huge clinical potential in the aspect of tumor treatment.

The invention provides a drug sustained release preparation for inhibiting vascular intimal hyperplasia and a preparation method and application thereof, and belongs to the technical field of biological medicine and vascular surgery. The drug sustained release preparation for inhibiting vascular intimal hyperplasia comprises a temperature-sensitive high polymer material and an MRTF / SRF pathway inhibitor, the temperature-sensitive high polymer material is a Pluronic type triblock copolymer; and the effective component of the MRTF / SRF pathway inhibitor is CCG222740 or CCG203971. The invention further discloses a preparation method of the MRTF / SRF pathway inhibitor. The drug sustained release preparation for inhibiting the vascular intimal hyperplasia can continuously release the MRTF / SRF pathway inhibitor at a fixed point in the AVF and other vascular injury repair process, can reduce at least 50% of neointimal area and vascular intimal-intimal thickness, and effectively inhibits the intimal hyperplasia.

The invention relates to the technical field of transdermal drug delivery, and discloses a transdermal drug delivery preparation of an indissolvable active compound and a preparation method of the transdermal drug delivery preparation. The preparation method comprises the following steps: respectively preparing the eutectic solvent and the polyelectrolyte aggregate; and blending the eutectic solvent and the polyelectrolyte aggregate, and then adding a drug for mixing to obtain the transdermal drug delivery preparation of the indissolvable active compound, or blending the eutectic solvent and the medicine, and then adding the polyelectrolyte aggregate for mixing to obtain the transdermal drug delivery preparation of the indissolvable active compound. According to the application, an innovative indissolvable active compound transdermal drug delivery preparation is constructed by taking a deep-eutectic solvent and polyelectrolyte aggregate composite system as a core, and the composition and the structure of the composite system and the interaction between the drug and the skin are optimized, so that efficient solubilization, synergistic infiltration promotion and stable slow release of the drug are realized; the preparation has good biocompatibility and safety, can solve many problems in transdermal administration of indissolvable active compounds, and improves the action effect and clinical application value of the drug.

The invention relates to the technical field of bacteriostatic agents, in particular to a plant perfume compound microorganism sustained release preparation as well as a preparation method and application thereof. The plant perfume compound microorganism sustained release preparation is prepared from the following raw materials in parts by mass: 2 to 4 parts of clove oil, 6 to 10 parts of citronellal, 1 part of an emulsifier, 2 to 4 parts of chitosan, 2 to 10 parts of sodium alginate, 2 to 6 parts of weathered coal humic acid, 2 to 6 parts of a compound bacterium agent, 10 to 20 parts of charcoal, 2 to 6 parts of amino-terminated polyamidoamine and 0.0002 to 0.0008 part of genipin. Through a triple synergistic mechanism of bacteriostasis of the complex microbial inoculant, slow release of plant active ingredients and rhizosphere micro-ecological regulation and control, the bottleneck that a single biotechnology is low in control effect and short in lasting effect is broken through, compared with chemical control, the cost is greatly reduced, and the method is suitable for an organic pineapple planting system and has remarkable economic and ecological benefits.

The application discloses a sustained-release preparation of indobufen and a preparation method and application thereof, and belongs to the technical field of pharmaceutical preparations. The application relates to a sustained-release preparation of indobufen and a preparation method and application thereof. The preparation has the characteristics of stable sustained-release effect, high bioavailability, good drug-taking compliance and small side effect, and is suitable for the prevention and / or treatment of diseases such as ischemic cardiovascular diseases, ischemic cerebrovascular diseases and venous thrombosis.

The invention provides a sitagliptin and metformin sustained-release pharmaceutical composition as well as a preparation method and application thereof, and relates to the technical field of sustained-release preparations. The pharmaceutical composition comprises a sustained-release tablet core and a quick-release coating layer, the sustained-release tablet core comprises an active ingredient metformin hydrochloride and a sustained-release framework material hydroxypropyl methylcellulose, and the sustained-release tablet core does not contain microcrystalline cellulose; the quick-release coating layer comprises an active component sitagliptin phosphate; the weight ratio of metformin hydrochloride to hydroxypropyl methylcellulose in the sustained release tablet core is 50: (24-27). The composition utilizes a double-layer structure to realize double-phase release of the medicine; the microcrystalline cellulose is removed, and the specific ratio of the active component to the framework material is limited, so that the moldability and ideal dissolution behavior of the preparation are ensured while the tablet weight is remarkably reduced to improve the swallowing compliance, and the technical problem that the slow-release framework function is difficult to maintain under the condition that the weight of a high-drug-loading-capacity compound preparation is greatly reduced is successfully solved.

The application provides a sitagliptin and metformin hydrochloride sustained-release pharmaceutical composition and a preparation method and application thereof, and relates to the technical field of sustained-release preparations. The pharmaceutical composition comprises a sustained-release tablet core and a quick-release coating layer; the sustained-release tablet core comprises active ingredients metformin hydrochloride and a sustained-release matrix material hydroxypropyl methyl cellulose, and the sustained-release tablet core does not contain microcrystalline cellulose; the quick-release coating layer comprises active ingredients sitagliptin phosphate; the weight ratio of metformin hydrochloride to hydroxypropyl methyl cellulose in the sustained-release tablet core is 50:(24-27). The composition realizes double-phase release of drugs by using a double-layer structure; by removing the microcrystalline cellulose and limiting the specific ratio of active ingredients to the matrix material, the forming property of the preparation and the ideal dissolution behavior are ensured while the tablet weight is significantly reduced to improve the swallowing compliance, and the technical problem that a high drug loading compound preparation is difficult to maintain the function of the sustained-release matrix under a large amount of weight reduction is successfully solved.

The present application relates to microspheres having a physiologically active substance uniformly dispersed therein and sustained-release preparations containing the same. In the present application, microspheres are provided, which are microspheres having a physiologically active substance uniformly dispersed therein with a lactic acid / glycolic acid copolymer (PLGA) as a main component, characterized in that the average volume-based particle diameter of the microspheres is 1 μm or more and 150 μm or less, and no lump or pore of the physiologically active substance of 1.5 μm or more is present in the microspheres. The microspheres of the present application can appropriately control the initial release amount of the physiologically active substance and the release rate during the period thereafter, and continuously release the physiologically active substance in vivo for a certain period.

The application discloses an exosome sustained-release preparation and application thereof in treatment of tendon injury, and the sustained-release preparation takes a silk fibroin frozen sponge as a carrier, and the carrier is loaded with exosomes. The application provides the silk fibroin frozen sponge as the carrier of the exosomes, and the silk fibroin frozen sponge has good biocompatibility and biodegradability; the sustained release of the exosomes is realized by controlling a protein fiber network structure of the silk fibroin. The application utilizes the silk fibroin frozen sponge to release the exosomes in situ at a tendon injury site, so that a better tendon repair effect is achieved.

The invention relates to the technical field of breeding regulation and control of black goats, in particular to a hormone treatment method for inducing estrus synchronization of black goats, which comprises the following steps: placing a CIDR vaginal suppository containing 1.38-1.56 g of progesterone into the vagina of an ewe, and keeping for 12-14 days; 48 hours before the thrombus is removed, intramuscularly injecting a sustained release preparation of 330 IU follicle-stimulating hormone and 30% polyvinylpyrrolidone; when the thrombus is removed, intramuscularly injecting a mixed solution containing 330IU pregnant mare serum gonadotropin and 0.1 mg of cloprostenol; 24 hours after the thrombus is removed, 25 micrograms of luteinizing hormone is intravenously injected to release hormone A3; single-time artificial insemination is performed within 48-56 hours after injection, 0.5 ml of semen is left for each injection, and the number of effective sperms is not less than 1.5 * 10 < 8 >. By precisely regulating and controlling CIDR progesterone and multi-hormone stepped injection, the estrus synchronization rate of a group is larger than or equal to 95%, and the traditional synchronization bottleneck is broken through; insemination parameters are controlled and optimized management is carried out, each fetal live lamb is 2.5-3.0, and the breeding efficiency is improved; treatment is started 45-50 days after delivery, the lambing interval is 210 + / -10 days, and large-scale efficient breeding is assisted.

The invention provides a tamsulosin hydrochloride sustained release preparation and a preparation method thereof, and belongs to the technical field of pharmaceutical preparations. The preparation method comprises the following steps: spraying an ethanol water solution of tamsulosin hydrochloride on a mesoporous silica carrier, and drying to obtain a drug-containing carrier; mixing the drug-containing carrier, an auxiliary carrier, an adhesive and water, and carrying out wet granulation to obtain a drug-containing soft material; extruding and rounding the medicine-containing soft material to obtain a medicine-containing pellet core; coating the drug-containing pellet core with a coating solution to obtain a coated pellet core; the coating liquid comprises an enteric-coated material and a plasticizer; and mixing the coated pellet core with a lubricant to obtain the tamsulosin hydrochloride sustained release preparation. The tamsulosin hydrochloride sustained-release preparation prepared by the method is good in drug content stability, stable in main drug release, simple in process, high in controllability and suitable for industrial production.

An indobufen sustained-release formulation, a preparation method therefor, and use thereof. The sustained-release formulation comprises: a main drug, a sustained-release material, a filler, and a binder. The sustained-release formulation achieves slow release of the drug and can continuously and stably release the active ingredient, thereby reducing the peak plasma concentration of the drug, and reducing gastrointestinal irritation. Furthermore, the preparation method is simple and easy to control, and features low cost and good process reproducibility, thus being suitable for large-scale industrial production.

The invention discloses a cat and dog gastrointestinal inflammation alleviator containing plant extracts and application of the cat and dog gastrointestinal inflammation alleviator, and relates to the field of pet health. The alleviator is prepared by compounding a plant extract component, a micro-ecological component, a functional auxiliary component and a carrier raw material, plant active components are purified by adopting an ultrasonic-assisted ethanol gradient elution combined membrane separation technology, and the problem of antagonism of a plant extract and probiotics is solved through microcapsule embedding and step-by-step compounding. The sustained-release preparation is prepared by combining sustained-release preparation forming and palatability optimization technologies. The traditional Chinese medicine composition can synergistically achieve the effects of resisting inflammation, repairing gastrointestinal mucosa, regulating intestinal flora and quickly stopping diarrhea, is suitable for preventing and treating acute and chronic enterogastritis of cats and dogs, and is good in palatability, high in stability, free of obvious toxic and side effects and convenient to administrate.

The present invention discloses a carrier with a drug sustained-release function and its application. The carrier is used to carry drugs and achieve a drug sustained-release effect. The carrier is in a gel state, a semi-solid state, or a solid state. The main component of the carrier is a fatty acid polyol ester, in which hydrogenated vegetable oil is dissolved. The carrier's morphology is adjusted by adjusting the amount of hydrogenated vegetable oil dissolved. The present invention mainly uses fatty acid polyol ester and hydrogenated vegetable oil to form a carrier, and then adds other drugs or compounds to achieve the purpose of sustained release. The sustained-release carrier can be prepared into an anhydrous gel, a semi-solid, or a solid, and can be used for the cavitary mucosa of animals and humans. The sustained-release carrier of the present invention does not destroy or reduce the efficacy of the active substance of the drug, and its sustained-release process is stable and effective, overcoming the shortcomings of traditional sustained-release preparations.

The invention relates to the technical field of pharmaceutical preparations, and particularly discloses an arginine ibuprofen biphasic sustained release preparation and a preparation method thereof. Through a two-phase system of quick-release particles and slow-release particles, the problems that a traditional preparation takes effect slowly, is short in medicine effect and poor in taste are solved. Wherein the quick-release granules are prepared by mixing and granulating ibuprofen arginine, a filling agent, an adhesive and a natural flavoring agent, so that the effective blood concentration can be ensured to be reached within 15 minutes after the medicine is orally taken so as to quickly relieve pain, and the bad flavor of the medicine can be synchronously covered; the sustained-release granules are based on an ibuprofen arginine drug-loading core, the outer layer of the sustained-release granules is coated with a sustained-release film formed by a sustained-release agent and a plasticizer, and the effective blood concentration can be stably maintained for 6-8 hours, so that the medicine taking frequency is reduced, the sustained-release granules only need to be taken for 1-2 times every day, the medication compliance of a patient is greatly improved, and the sustained-release granules are suitable for clinical application. The traditional Chinese medicine composition is especially suitable for clinical scenes needing long-term or repeated analgesia such as chronic arthritis and postoperative pain, has excellent safety and practicability, and has a wide market application prospect.

The invention discloses a hydroxyapatite modified drug-loaded slow-release nanofiber and a preparation method thereof, the hydroxyapatite modified drug-loaded slow-release nanofiber has a fusiform structure, the fusiform structure is formed by a skeleton formed by wrapping porous hydroxyapatite in a porous nanofiber, and the skeleton is loaded with a hydrophilic drug; the porous nanofiber comprises a hydrophilic high polymer material and a hydrophobic high polymer material. Meanwhile, hydroxyapatite capable of adsorbing hydrophilic drugs is selected as a drug carrier, then electrostatic spinning is conducted on the drug carrier, the advantages of hydroxyapatite and hydroxyapatite are fully exerted through combination of hydroxyapatite and hydroxyapatite, and the sustained-release preparation prepared through the method can effectively improve the sustained-release effect and the accumulative utilization rate of the drugs in the human body.

A brivaracetam pharmaceutical composition contains an active pharmaceutical ingredient, a matrix forming agent, and a swelling agent. It has a sustained release effect and has a more flat release curve compared with a common gel skeleton sustained-release preparation, and thus achieves the purposes of reducing the release rate of the medicament, controlling the in vivo effective dosage of the medicament, stabilizing the blood concentration, reducing toxic and side effects and reducing the times of daily administration.

To provide a sustained-release preparation.SOLUTION: The sustained-release preparation contains, based on the total weight of the preparation, an active ingredient comprising an acetone extract of gamboge resin in an amount of 25.00 wt.% to 31.25 wt.%, sodium lauryl sulfate in an amount of 4 wt.% to 25 wt.%, hydroxypropyl methylcellulose in an amount of 15.63 wt.% to 23.44 wt.%, microcrystalline cellulose in an amount of 6.25 wt.% to 13.38 wt.%, silicon dioxide in an amount of 0.63 wt.% to 1.56 wt.%, magnesium stearate in an amount of 0.63 wt.% to 1.56 wt.%, lactose in an amount of 25.00 wt.% to 40.13 wt.%, and dextrose in an amount of 5.00 wt.% to 7.81 wt.%.SELECTED DRAWING: Figure 2

The invention belongs to the field of pharmaceutical preparations, and relates to a pentoxifylline sustained-release preparation, which comprises pentoxifylline as an active component, and a sustained-release material, an adhesive, a glidant and a lubricant as auxiliary materials, and the component of the slow-release skeleton is hydroxyethyl cellulose. Wherein each sustained-release tablet contains 200-700 parts by weight of pentoxifylline, and drug release is controlled by adding a sustained-release material; meanwhile, by adopting a secondary granulation technology, the drug release speed can be effectively slowed down, and the drug treatment time can be prolonged. The prescription preparation technology is simple and convenient, and commercialized production is easy to realize.

The invention discloses a polymer, the polymer comprises a diphenylboronic acid structural unit capable of being combined with glucose and a hydrophilic polymerizable structural unit, and the diphenylboronic acid structural unit can improve the combining capacity and selectivity of glucose. The invention further discloses an insulin sustained release preparation containing the polymer, the preparation has different insulin release rates under different glucose concentrations, insulin release is accelerated in a hyperglycemia environment to reduce blood sugar, and the preparation can reduce insulin wrong release caused by fructose and other diol substances. The invention also discloses a preparation method of the insulin sustained-release preparation. The insulin sustained-release preparation is prepared by self-assembling negatively charged insulin and positively charged bisphenylboronic acid modified polymer through electrostatic interaction, and the insulin sustained-release preparation has the characteristic of high load rate. The prepared insulin sustained-release preparation can release insulin, and the blood glucose level can be reduced after the released insulin is combined with an insulin receptor in a body.

The invention provides arbidol hydrochloride sustained release tablets as well as a preparation method and application thereof, and belongs to the technical field of medicines. The preparation method comprises the following steps: performing water extraction and alcohol precipitation on liquorice, ginger and flos puerariae to obtain hydrophilic active polysaccharide, performing ionic liquid separation to obtain an active component, mixing arbidol hydrochloride, biotoxin and the active component to prepare liposome, uniformly mixing the liposome with lactose, cross-linked povidone and the hydrophilic active polysaccharide, and preparing quick-release particles by using a povidone K30 solution and magnesium stearate; mixing arbidol hydrochloride and microcrystalline cellulose, and preparing sustained-release particles by using ethanol and magnesium stearate; the arbidol hydrochloride sustained-release tablet has the double properties of sustained release and quick release, the sustained-release effect reduces the administration frequency, and the quick-release effect can enable the blood concentration to quickly rise, so that the drug effect is quickly exerted to generate a treatment effect, the defect that a common sustained-release preparation takes effect slowly is overcome, and the arbidol hydrochloride sustained-release tablet is suitable for clinical application. The preparation method is simple, convenient and suitable for industrial production.

The invention relates to the technical field of biological medicines, in particular to application of biotin medicines and application of a biotin sustained release preparation. Biotin drugs are used for preparing drugs for promoting cartilage formation, retarding osteoarthritis progress and inhibiting cartilage loss, and can effectively relieve and treat osteoarthritis.

The invention discloses a preparation method of a traditional Chinese medicine composition for treating skin tinea, allergic dermatitis and acne, and relates to the field of pharmaceutical preparations, the extraction rate of gallic acid and ethyl gallate contained in total tannin in fructus chebulae flesh, fructus terminaliae billericae flesh and fructus chebulae immaturus is improved through an enzymolysis method, and the transfer rate of effective components of quercetin is improved through a boiling granulation technology; therefore, the effect of treating psoriasis of the composition is improved. By adopting a boiling granulation technology, the technical problems of long preparation period and high cost in the prior art are solved. The release speed of aloe in intestinal tracts is controlled by adopting a slow release technology, and the upper and lower limit content range of barbaloin is controlled to reduce the occurrence rate of adverse reactions of the composition. Meanwhile, butyl hydroxy anisd (BHA), butylated hydroxytoluene (BHT) and a citric acid system are adopted, so that the problems of PEO skeleton degradation, out-of-control drug release behavior and insufficient main drug stability of the barbaloin-PEO sustained release preparation are solved.

The invention discloses a raw material quantitative weighing method and device for preparing a metformin compound sustained release preparation, and relates to the technical field of physical weighing, the raw material quantitative weighing device comprises a raw material mixing box, the top of the raw material mixing box is fixedly provided with a related frame, the top of the related frame is fixedly provided with an annular supporting plate, and the annular supporting plate is fixedly provided with an annular groove; a variable weighing mechanism is arranged on the outer surface wall of the annular supporting plate, a boosting discharging mechanism is arranged at the top of the annular supporting plate and comprises an assembling plate, the bottom of the assembling plate is fixedly installed at the top of the annular supporting plate, a locking sleeve is fixedly installed in the assembling plate, and the locking sleeve is fixedly installed on the top of the annular supporting plate. According to the mechanism, a sectional raw material lowering method is adopted, raw materials are subjected to fluffy treatment in advance, the characteristic that powder particle raw materials are prone to being stacked is improved, the raw materials are transferred into a designated container in a slow scattering mode, it is guaranteed that the weighing assembly more easily captures tiny numerical value changes, and the weighing accuracy is improved. And the error between each raw material and the set standard value is reduced.